DeepMed Research

UNIVERSITY COLLEGE LONDON

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private

Established: 1826-02-11

Employees: 10K

Market Cap: -

Website: http://www.ucl.ac.uk

Clinical Trials

Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Phase 1

Completed

Conditions: Neurotoxicity
Chemotherapeutic Agent Toxicity
Mucositis
Lymphoma

First Posted Date: 2008-08-04

Last Posted Date: 2014-01-27

Lead Sponsor: University College, London

Target Recruit Count: 4

Registration Number: NCT00727831

Locations: 🇬🇧
Leeds General Infirmary, Leeds, England, United Kingdom
🇬🇧
Torbay Hospital, Torquay, England, United Kingdom

Promoting Physical Activity in the Over 65s

Phase 3

Conditions: Falls

Interventions: Behavioral: Otago Exercise Programme
Behavioral: Fame
Other: Treatment As Usual

First Posted Date: 2008-08-01

Last Posted Date: 2010-07-08

Lead Sponsor: University College, London

Target Recruit Count: 1200

Registration Number: NCT00726531

Locations: 🇬🇧
University College London, London, United Kingdom
🇬🇧
University of Nottingham, Nottingham, United Kingdom

The Role of Dendritic Cells in Hepatitis C Infection

Not Applicable

Completed

Conditions: Chronic Hepatitis C Infection

First Posted Date: 2008-07-28

Last Posted Date: 2008-07-28

Lead Sponsor: University College, London

Registration Number: NCT00723242

Locations: 🇬🇧
University College Hospital, London, United Kingdom

Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Biological: bleomycin sulfate
Biological: filgrastim
Drug: dacarbazine
Biological: pegfilgrastim
Drug: doxorubicin hydrochloride
Drug: vinblastine sulfate
Drug: cyclophosphamide
Drug: etoposide
Drug: prednisolone
Drug: procarbazine hydrochloride
Drug: vincristine sulfate

First Posted Date: 2008-05-15

Last Posted Date: 2024-05-08

Lead Sponsor: University College, London

Target Recruit Count: 1202

Registration Number: NCT00678327

Locations: 🇬🇧
Southampton General Hospital, Southampton, England, United Kingdom

Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma

Phase 2

Completed

Conditions: Neurotoxicity
Lymphoma

Interventions: Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Drug: etoposide
Drug: prednisolone
Drug: procarbazine hydrochloride
Radiation: radiation therapy
Drug: vincristine sulfate

First Posted Date: 2008-04-25

Last Posted Date: 2014-12-04

Lead Sponsor: University College, London

Target Recruit Count: 47

Registration Number: NCT00666484

Locations: 🇬🇧
University College Hospital - London, London, England, United Kingdom
🇬🇧
Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
🇬🇧
King's College Hospital, London, England, United Kingdom

and more 2 locations

Dopamine Agonist for Hemispatial Neglect and Motor Deficit Post Stroke

Phase 2

Completed

Conditions: Right Hemisphere Stroke
Hemispatial Neglect
Motor Deficit

Interventions: Drug: Rotigotine

First Posted Date: 2008-04-22

Last Posted Date: 2011-02-21

Lead Sponsor: University College, London

Target Recruit Count: 20

Registration Number: NCT00663338

Locations: 🇬🇧
Homerton University Hospital, London, United Kingdom
🇬🇧
The National Hospital for Neurology & Neurosurgery, London, United Kingdom
🇬🇧
Charing Cross Hospital, London, United Kingdom

Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: bexarotene
Drug: gemcitabine hydrochloride

First Posted Date: 2008-04-17

Last Posted Date: 2014-12-03

Lead Sponsor: University College, London

Target Recruit Count: 36

Registration Number: NCT00660231

Locations: 🇬🇧
Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
🇬🇧
St. Thomas' Hospital, London, England, United Kingdom
🇬🇧
Royal Cornwall Hospital, Truro, England, United Kingdom

and more 4 locations

Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis

Phase 1

Completed

Conditions: Retinal Degeneration

Interventions: Biological: tgAAG76 (rAAV 2/2.hRPE65p.hRPE65)

First Posted Date: 2008-03-26

Last Posted Date: 2015-12-07

Lead Sponsor: University College, London

Target Recruit Count: 12

Registration Number: NCT00643747

Locations: 🇬🇧
Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom

Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2008-03-21

Last Posted Date: 2018-10-31

Lead Sponsor: University College, London

Target Recruit Count: 370

Registration Number: NCT00641095

Locations: 🇬🇧
Newcastle Upon Tyne Hospitals NHS Trust, Newcastle-Upon-Tyne, England, United Kingdom
🇬🇧
Pontefract General Infirmary, Pontefract, England, United Kingdom
🇬🇧
Saint Bartholomew's Hospital, London, England, United Kingdom

and more 64 locations

WBRT & Erlotinib in Advanced NSCLC and Brain Metastases

Phase 2

Terminated

Conditions: Lung Cancer
Metastatic Cancer

Interventions: Drug: erlotinib hydrochloride
Drug: placebo

First Posted Date: 2007-11-07

Last Posted Date: 2011-12-12

Lead Sponsor: University College, London

Target Recruit Count: 80

Registration Number: NCT00554775

Locations: 🇬🇧
University College of London Hospitals, London, England, United Kingdom
🇬🇧
Salisbury District Hospital, Salisbury, England, United Kingdom
🇬🇧
Christie Hospital, Manchester, England, United Kingdom

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy